- Monopar Therapeutics announced the presentation of new long-term neurological efficacy and safety data for its investigational therapy **ALXN1840** for Wilson disease at the **150th American Neurological Association (ANA) Annual Meeting** on **September 14-15, 2025**.  **[1645469_0001437749-25-029005_ex_861328.htm:0]** **[1645469_0001437749-25-029005_mnpr20250912_8k.htm:1]** 
- The analysis included pooled efficacy outcomes from **three independent clinical trials (n=255)** and safety data from **four independent clinical trials (n=266)**, with a median treatment duration of approximately **2.6 years**.  **[1645469_0001437749-25-029005_ex_861328.htm:0]** 
- Key findings showed **statistically significant sustained neurological improvement** from baseline over **6 years** and **psychiatric improvement** over multiple years.  **[1645469_0001437749-25-029005_ex_861328.htm:1]** 
- Patients who crossed over from standard of care to ALXN1840 demonstrated **additional neurological improvement**, with most reversing worsening experienced on standard of care.  **[1645469_0001437749-25-029005_ex_861328.htm:1]** 
- ALXN1840 exhibited a **favorable safety profile**, with less than **1%** of patients experiencing a drug-related neurological serious adverse event across more than **645 patient-years**.  **[1645469_0001437749-25-029005_ex_861328.htm:1]**

Monopar Therapeutics (MNPR)